drugset / Trial / NCT05725005
PET Study of Repeated ASN51 in Healthy Volunteers
Phase 1
Completed
12 enrolled
Asceneuron S.A.
Hammersmith Medicines Research · collabInvicro · collab
Non-randomizedSequentialOpen-labelOther
Summary
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs), after repeated doses of ASN51 in healthy participants.
Timeline
- Start
- 2023-01-26
- Primary completion
- 2023-04-04
- Completion
- 2023-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASN51 | Unknown | — | Oral |
Indications
No indication recorded.